Skip to main content

Free Content Commentary

Download Article:
(PDF 108.8 kb)
Parkinson's disease (PD), the most frequent movement disorder, is caused by the progressive loss of the dopamine neurons within the substantia nigra pars compacta and the associated deficiency of the neurotransmitter dopamine in the striatum. Most cases of PD are of a sporadic nature whose cause is unknown, while mutations in several genes have been linked to genetic forms of PD (α-synuclein, Parkin, DJ-1, PINK1, and LRRK2). Epidemiological studies in humans, as well as molecular studies in toxin-induced (e.g. 6-hydroxydopamine (6-OHDA) and rotenone) and genetic animal models of PD show that mitochondrial dysfunction, especially Complex I, is a defect occurring early in the pathogenesis of both sporadic and familial PD. Mitochondrial dynamics (fission, fusion, migration) are important for neurotransmission, synaptic maintenance and neuronal survival.....
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: Scienze del Farmaco University of Padova Padova, Italy.

Publication date: 01 May 2012

More about this publication?
  • CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more